These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32803700)

  • 21. Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.
    Brueckl WM; Achenbach HJ; Ficker JH; Schuette W
    BMC Cancer; 2018 Mar; 18(1):333. PubMed ID: 29587656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
    Fan Y; Huang ZY; Yu HF; Luo LH
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.
    Tarhini AA; Rafique I; Floros T; Tran P; Gooding WE; Villaruz LC; Burns TF; Friedland DM; Petro DP; Farooqui M; Gomez-Garcia J; Gaither-Davis A; Dacic S; Argiris A; Socinski MA; Stabile LP; Siegfried JM
    Cancer; 2017 Aug; 123(15):2936-2944. PubMed ID: 28472537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients.
    Tani T; Naoki K; Yasuda H; Arai D; Ishioka K; Ohgino K; Yoda S; Nakayama S; Satomi R; Terai H; Ikemura S; Sato T; Soejima K
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):1065-1071. PubMed ID: 31493177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer.
    Padda SK; Reckamp KL; Koczywas M; Neal JW; Kawashima J; Kong S; Huang DB; Kowalski M; Wakelee HA
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):105-115. PubMed ID: 34773474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer.
    Li T; Piperdi B; Walsh WV; Kim M; Beckett LA; Gucalp R; Haigentz M; Bathini VG; Wen H; Zhou K; Pasquinelli PB; Gajavelli S; Sreedhara M; Xie X; Lara PN; Gandara DR; Perez-Soler R
    Clin Lung Cancer; 2017 Jan; 18(1):60-67. PubMed ID: 27919627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment Patterns by EGFR Mutation Status in Non-Small Cell Lung Cancer Patients in the USA: A Retrospective Database Analysis.
    Aguilar KM; Winfree KB; Muehlenbein CE; Zhu YE; Wilson T; Wetmore S; Nadler ES
    Adv Ther; 2018 Nov; 35(11):1905-1919. PubMed ID: 30341504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination TS-1 plus EGFR-tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer after progression on first-line or further EGFR-TKIs: A phase II, single-arm trial.
    Yang L; Yang S; Liu Y; Li J; Hu X; Wang Y; Zhang Y; Wang Y
    Thorac Cancer; 2018 Jun; 9(6):693-698. PubMed ID: 29655198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.
    Rosell R; Dafni U; Felip E; Curioni-Fontecedro A; Gautschi O; Peters S; Massutí B; Palmero R; Aix SP; Carcereny E; Früh M; Pless M; Popat S; Kotsakis A; Cuffe S; Bidoli P; Favaretto A; Froesch P; Reguart N; Puente J; Coate L; Barlesi F; Rauch D; Thomas M; Camps C; Gómez-Codina J; Majem M; Porta R; Shah R; Hanrahan E; Kammler R; Ruepp B; Rabaglio M; Kassapian M; Karachaliou N; Tam R; Shames DS; Molina-Vila MA; Stahel RA;
    Lancet Respir Med; 2017 May; 5(5):435-444. PubMed ID: 28408243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.
    Nishio M; Horiike A; Murakami H; Yamamoto N; Kaneda H; Nakagawa K; Horinouchi H; Nagashima M; Sekiguchi M; Tamura T
    Lung Cancer; 2015 Jun; 88(3):275-81. PubMed ID: 25891541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).
    Lim SM; Cho BC; Kim SW; Kang SY; Heo DS; Kim HT; Lee DH; Kim DW; Jung M; Choi JH; Shim HS; Choi JR; Kim JH
    Lung Cancer; 2016 Mar; 93():1-8. PubMed ID: 26898607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202).
    Miyanaga A; Kubota K; Hosomi Y; Okuma Y; Minato K; Fujimoto S; Okamoto H; Satouchi M; Isobe H; Aono H; Takiguchi Y; Gemma A;
    Jpn J Clin Oncol; 2019 Aug; 49(8):749-754. PubMed ID: 31070750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carboplatin, S-1 and concurrent thoracic radiotherapy for elderly patients with locally advanced non-small cell lung cancer: a multicenter Phase I/II study.
    Niho S; Hosomi Y; Okamoto H; Nihei K; Tanaka H; Hida T; Umemura S; Goto K; Akimoto T; Ohe Y
    Jpn J Clin Oncol; 2019 Jul; 49(7):614-619. PubMed ID: 30916304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer.
    Shimizu T; Nishio K; Sakai K; Okamoto I; Okamoto K; Takeda M; Morishita M; Nakagawa K
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):211-219. PubMed ID: 32638093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.
    Macaulay VM; Middleton MR; Eckhardt SG; Rudin CM; Juergens RA; Gedrich R; Gogov S; McCarthy S; Poondru S; Stephens AW; Gadgeel SM
    Clin Cancer Res; 2016 Jun; 22(12):2897-907. PubMed ID: 26831715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer.
    Chihara Y; Yoshimura A; Date K; Takemura Y; Tamiya N; Kohno Y; Imabayashi T; Takeuchi M; Kaneko Y; Yamada T; Ueda M; Arimoto T; Uchino J; Iwasaki Y; Takayama K
    Oncologist; 2019 Aug; 24(8):1033-e617. PubMed ID: 31040252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switch maintenance chemotherapy using S-1 with or without bevacizumab in patients with advanced non-small cell lung cancer: a phase II study.
    Niho S; Ohe Y; Ohmatsu H; Umemura S; Matsumoto S; Yoh K; Goto K
    Lung Cancer; 2017 Jun; 108():66-71. PubMed ID: 28625650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer.
    Bhateja P; Dowlati A; Sharma N
    Invest New Drugs; 2018 Jun; 36(3):435-441. PubMed ID: 28971268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
    Pennell NA; Neal JW; Chaft JE; Azzoli CG; Jänne PA; Govindan R; Evans TL; Costa DB; Wakelee HA; Heist RS; Shapiro MA; Muzikansky A; Murthy S; Lanuti M; Rusch VW; Kris MG; Sequist LV
    J Clin Oncol; 2019 Jan; 37(2):97-104. PubMed ID: 30444685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer.
    Kishi K; Sakai H; Seto T; Kozuki T; Nishio M; Imamura F; Nokihara H; Satouchi M; Nakagawa S; Tahata T; Nakagawa K
    Cancer Treat Res Commun; 2019; 18():100113. PubMed ID: 30472556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.